CommercialAdministrativeLow impact
08.02.15, Lovotibeglogene autotemcel (Lyfgenia®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of the policy for Lovotibeglogene autotemcel (Lyfgenia®), a gene therapy medication. The policy is being reissued with an effective date of April 29, 2026, indicating this is likely a routine policy renewal or update for this specialized pharmacy benefit.
Action Required
By April 29, 2026: Review updated Lyfgenia® policy for any changes to coverage criteria or prior authorization requirements. This affects gene therapy billing and may require updates to prior authorization workflows if changes are made to the reissued policy.